NUVL

NUVL

USD

Nuvalent Inc. Class A Common Stock

$92.690-1.560 (-1.655%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$94.250

高値

$95.225

安値

$92.075

出来高

0.28M

企業ファンダメンタルズ

時価総額

6.7B

業種

バイオテクノロジー

United States

取引統計

平均出来高

0.46M

取引所

NMS

通貨

USD

52週レンジ

安値 $55.535現在値 $92.690高値 $104.9

関連ニュース

PR Newswire

Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

もっと見る
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
Analyst Upgrades

UBS Maintains Buy on Nuvalent, Raises Price Target to $132

UBS analyst David Dai maintains Nuvalent with a Buy and raises the price target from $114 to $132.

もっと見る
UBS Maintains Buy on Nuvalent, Raises Price Target to $132
PR Newswire

Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

もっと見る
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Piper Sandler Maintains Overweight on Nuvalent, Raises Price Target to $128

Piper Sandler analyst Kelsey Goodwin maintains Nuvalent with a Overweight and raises the price target from $112 to $128.

もっと見る
Piper Sandler Maintains Overweight on Nuvalent, Raises Price Target to $128

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。